A Phase 2 interventional study of Tislelizumab in Hepatocellular Carcinoma (HCC), sponsored by BeiGene. Completed at 54 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.
Sponsored by BeiGene · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tislelizumab in Carcinoma, Hepatocellular — 23 open to participants now, 25 under way, 2 of them phase 3. tislelizumab · Carcinoma, Hepatocellular.
Among the 43 studies testing tislelizumab in Carcinoma, Hepatocellular, this one is the 3rd largest by enrollment, is the only one that started in 2018, is one of 31 in phase 2, and was the 2nd registered.
3,653 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,065 are open to participants now.
Browse Carcinoma, Hepatocellular studies →23 of the 43 studies testing tislelizumab in Carcinoma, Hepatocellular are open now, in 2 countries. Recruiting first, the newest first:
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
First Hospital of China Medical University · Sites in China
Ages 18–80
Tongji Hospital · Sites in China
Ages 18+
Haibo Shao · Sites in China
Ages 18–80
Sir Run Run Shaw Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 741 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 251 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 32 · Phase 3 4 · Phase 4 1
First in 2017; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 249 is above the median of 53 across 2,621 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 40 across the 43 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 43 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
BeOne Medicines has 9 studies filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
5 of the studies testing tislelizumab in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04615143Sun Yat-sen UniversityTislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC | 2026-12-01 |
| NCT07413354Tongji HospitalTislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma | 2027-03-31 |
| NCT07483359First Hospital of China Medical UniversityConversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus | 2027-06 |
| NCT05366829Rutgers, The State University of New JerseyTislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma | 2027-06-01 |
| NCT07243691Sir Run Run Shaw HospitalStudy on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma | 2027-11-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 43 studies testing tislelizumab in Carcinoma, Hepatocellular, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigated the efficacy, safety, and pharmacokinetics of the anti-PD-1 monoclonal antibody BGB-A317 in participants with previously treated hepatocellular unresectable carcinoma.
Key Inclusion Criteria:
Key Exclusion Criteria:
Has received:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
200 milligrams once every 3 weeks
Drug: Tislelizumab
Administered intravenously
Also known as: BGB-A317
Objective Response Rate (ORR) Assessed by Independent Review Committee (IRC)
ORR is defined as the percentage of participants with complete response (CR) and partial response (PR) as the best overall response, as determined by an IRC using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR is defined as disappearance of all target lesions and PR is defined as at least a 30% decrease in the sum of diameters of target lesions.
Time frame: From date of first dose to primary analysis data cut-off date of 30-June-2021 (up to approximately 3 years and 3 months)
ORR Assessed by Investigator
ORR is defined as the percentage of participants with CR and PR as the best overall response, as determined by investigator assessment using RECIST v1.1. CR is defined as disappearance of all target lesions and PR is defined as at least a 30% decrease in the sum of diameters of target lesions.
Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months)
Duration of Response (DOR) Assessed by IRC
DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the IRC using RECIST v1.1
Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months)
DOR Event-Free Rate Assessed by IRC
DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the IRC using RECIST v1.1. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for progression or death at 12 and 24 months with 95% confidence intervals estimated using Greenwood's formula.
Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months); Months 12 and 24 reported
DOR Assessed by Investigator
DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the investigator using RECIST v1.1
Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months)
DOR Event-Free Rate Assessed by Investigator
DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the investigator using RECIST v1.1. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for progression or death at 12 and 24 months with 95% confidence intervals estimated using Greenwood's formula.
Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months); Months 12 and 24 reported
Progression-free Survival (PFS) Assessed by IRC
PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the IRC using RECIST v1.1
Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months)
PFS Assessed by Investigator
PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the investigator using RECIST v1.1
Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months)
Overall Survival (OS)
OS is defined as the time from first study drug administration to the date of death due to any cause
Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months)
Disease Control Rate (DCR) Assessed by IRC
DCR is defined as the percentage of participants whose best overall response is CR, PR, or stable disease (SD) as assessed by the IRC using RECIST v1.1
Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months)
DCR Assessed by Investigator
DCR is defined as the percentage of participants whose best overall response is CR, PR, or stable disease (SD) as assessed by the investigator using RECIST v1.1
Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months)
Clinical Benefit Rate (CBR) Assessed by IRC
CBR is defined as the percentage of participants who have CR, PR, or SD of ≥ 24 weeks in duration as assessed by the IRC using RECIST v1.1
Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months)
CBR Assessed by Investigator
CBR is defined as the percentage of participants who have CR, PR, or SD of ≥ 24 weeks in duration as assessed by the investigator using RECIST v1.1
Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months)
European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) Visual Analogue Score (VAS)
Mean change from baseline in EQ-5D-5L VAS. The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.
Time frame: Baseline to Cycle 6 Day 1 and Cycle 12 Day 1 (each cycle is 21 days)
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status
Mean change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.
Time frame: Baseline to Cycle 6 Day 1 and Cycle 12 Day 1 (each cycle is 21 days)
EORTC QLQ - Hepatocellular Carcinoma 18 Questions (HCC18): Index Scores
Mean change from baseline in EORTC QLQ HCC18 Index Scores. The EORTC QLQ HCC18 is a specific questionnaire module that assesses quality of life of cancer patients related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.
Time frame: Baseline to Cycle 6 Day 1 and Cycle 12 Day 1 (each cycle is 21 days)
Number of Participants With Adverse Events
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs
Time frame: From first dose up to 30 days after the last dose of study drug; up to approximately 4 years and 3 months
This study was conducted at 73 study centers in Mainland China, Taiwan, Italy, Germany, France, Spain, Poland, and the United Kingdom.
| Milestone | Tislelizumab |
|---|---|
| Started | 249 |
| Completed | 0 |
| Not completed | 249 |
| Withdrew: Death | 180 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Sponsor decision | 61 |
| Withdrew: Physician decision | 1 |
ORR is defined as the percentage of participants with complete response (CR) and partial response (PR) as the best overall response, as determined by an IRC using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR is defined as disappearance of all target lesions and PR is defined as at least a 30% decrease in the sum of diameters of target lesions.
| Percentage of participants | Tislelizumab |
|---|---|
| Objective Response Rate (ORR) Assessed by Independent Review Committee (IRC) | 12.9 (8.96 to 17.66) |
ORR is defined as the percentage of participants with CR and PR as the best overall response, as determined by investigator assessment using RECIST v1.1. CR is defined as disappearance of all target lesions and PR is defined as at least a 30% decrease in the sum of diameters of target lesions.
| Percentage of participants | Tislelizumab |
|---|---|
| ORR Assessed by Investigator | 14.5 (10.34 to 19.45) |
DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the IRC using RECIST v1.1
| Months | Tislelizumab |
|---|---|
| Duration of Response (DOR) Assessed by IRC | NA (14.6 to NA) |
DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the IRC using RECIST v1.1. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for progression or death at 12 and 24 months with 95% confidence intervals estimated using Greenwood's formula.
| Percentage of participants | Tislelizumab |
|---|---|
| 12 Months | 76.9 (57.5 to 88.3) |
| 24 Months | 65.9 (45.7 to 80.1) |
DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the investigator using RECIST v1.1
| Months | Tislelizumab |
|---|---|
| DOR Assessed by Investigator | 21.4 (11.1 to NA) |
DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the investigator using RECIST v1.1. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for progression or death at 12 and 24 months with 95% confidence intervals estimated using Greenwood's formula.
| Percentage of participants | Tislelizumab |
|---|---|
| 12 Months | 68.1 (49.8 to 80.9) |
| 24 Months | 47.4 (30.1 to 62.8) |
PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the IRC using RECIST v1.1
| Months | Tislelizumab |
|---|---|
| Progression-free Survival (PFS) Assessed by IRC | 2.7 (1.4 to 2.8) |
PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the investigator using RECIST v1.1
| Months | Tislelizumab |
|---|---|
| PFS Assessed by Investigator | 2.8 (2.6 to 4.0) |
OS is defined as the time from first study drug administration to the date of death due to any cause
| Months | Tislelizumab |
|---|---|
| Overall Survival (OS) | 13.2 (10.8 to 15.2) |
DCR is defined as the percentage of participants whose best overall response is CR, PR, or stable disease (SD) as assessed by the IRC using RECIST v1.1
| Percentage of participants | Tislelizumab |
|---|---|
| Disease Control Rate (DCR) Assessed by IRC | 53.0 (46.61 to 59.34) |
DCR is defined as the percentage of participants whose best overall response is CR, PR, or stable disease (SD) as assessed by the investigator using RECIST v1.1
| Percentage of participants | Tislelizumab |
|---|---|
| DCR Assessed by Investigator | 59.0 (52.65 to 65.20) |
CBR is defined as the percentage of participants who have CR, PR, or SD of ≥ 24 weeks in duration as assessed by the IRC using RECIST v1.1
| Percentage of participants | Tislelizumab |
|---|---|
| Clinical Benefit Rate (CBR) Assessed by IRC | 22.5 (17.46 to 28.19) |
CBR is defined as the percentage of participants who have CR, PR, or SD of ≥ 24 weeks in duration as assessed by the investigator using RECIST v1.1
| Percentage of participants | Tislelizumab |
|---|---|
| CBR Assessed by Investigator | 30.9 (25.24 to 37.07) |
Mean change from baseline in EQ-5D-5L VAS. The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.
| Score on a scale | Tislelizumab |
|---|---|
| Baseline | 75.2 ± 18.36 |
| Change at Cycle 6 | 2.4 ± 12.57 |
| Change at Cycle 12 | 4.7 ± 13.85 |
Mean change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.
| Score on a scale | Tislelizumab |
|---|---|
| Baseline | 71.8 ± 19.37 |
| Change at Cycle 6 | -0.1 ± 17.50 |
| Change at Cycle 12 | 1.1 ± 18.63 |
Mean change from baseline in EORTC QLQ HCC18 Index Scores. The EORTC QLQ HCC18 is a specific questionnaire module that assesses quality of life of cancer patients related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.
| Score on a scale | Tislelizumab |
|---|---|
| Baseline | 13.6 ± 11.33 |
| Change at Cycle 6 | 1.4 ± 11.77 |
| Change at Cycle 12 | 0.1 ± 8.27 |
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs
| Participants | Tislelizumab |
|---|---|
| Participants with at least 1 TEAE | 236 |
| Participants with a serious TEAE | 94 |
Collected over From first dose to 30 days after last dose of study drug (up to approximately 4 years and 3 months). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tislelizumab | 180/249 (72.3%) | 94/249 (37.8%) | 226/249 (90.8%) |
| Event | Tislelizumab |
|---|---|
| AscitesGastrointestinal disorders | 9/249 |
| Hepatic failureHepatobiliary disorders | 7/249 |
| PneumoniaInfections and infestations | 5/249 |
| Aspartate aminotransferase increasedInvestigations | 5/249 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 4/249 |
| Hepatic function abnormalHepatobiliary disorders | 4/249 |
| Abdominal painGastrointestinal disorders | 3/249 |
| General physical health deteriorationGeneral disorders | 3/249 |
| SepsisInfections and infestations | 3/249 |
| Blood bilirubin increasedInvestigations | 3/249 |
| Event | Tislelizumab |
|---|---|
| Aspartate aminotransferase increasedInvestigations | 66/249 |
| Alanine aminotransferase increasedInvestigations | 52/249 |
| Blood bilirubin increasedInvestigations | 48/249 |
| Decreased appetiteMetabolism and nutrition disorders | 43/249 |
| AstheniaGeneral disorders | 40/249 |
| PruritusSkin and subcutaneous tissue disorders | 35/249 |
| AnaemiaBlood and lymphatic system disorders | 32/249 |
| PyrexiaGeneral disorders | 32/249 |
| DiarrhoeaGastrointestinal disorders | 30/249 |
| CoughRespiratory, thoracic and mediastinal disorders | 30/249 |
| Age, Continuous(Years) | Tislelizumab |
|---|---|
| Mean | 60.3 ± 12.54 |
| Sex: Female, Male(Participants) | Tislelizumab |
|---|---|
| Female | 32 |
| Male | 217 |
| Race/Ethnicity, Customized(Participants) | Tislelizumab |
|---|---|
| Asian | 123 |
| White | 47 |
| Other | 1 |
| Not Reported | 78 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status Score(Participants) | Tislelizumab |
|---|---|
| 0 = Fully Active | 129 |
| 1 = Restricted Activity | 120 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Apr 2018 to primary completion in Jun 2021, 38 months.
Results were first posted in Jul 2023, 2 years after primary completion. A results delay was requested in Jun 2022.
Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 38 months is close to that.
Counting every sponsor, half of 430 studies reached it within 43 months; a quarter within 30 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tislelizumab